APOE ε4 carriers had a faster decline in ADAS-cog 13 score than APOE ε4 non-carriers in both cohorts (p = 0.0036 for preclinical AD, p < 0.0001 for MCI due to AD). The gene discussed is APOE; the disease is Alzheimer disease.